作者
P Krishna Murthy, Karthikeyan Sivashanmugam, Mahesh Kandasamy, Rajasekaran Subbiah, Vilwanathan Ravikumar
发表日期
2021/2/1
来源
Life sciences
卷号
266
页码范围
118883
出版商
Pergamon
简介
Coronavirus disease 2019 (COVID-19) has rapidly spread around the world causing global public health emergency. In the last twenty years, we have witnessed several viral epidemics such as severe acute respiratory syndrome coronavirus (SARS-CoV), Influenza A virus subtype H1N1 and most recently Middle East respiratory syndrome coronavirus (MERS-CoV). There were tremendous efforts endeavoured globally by scientists to combat these viral diseases and now for SARS-CoV-2. Several drugs such as chloroquine, arbidol, remdesivir, favipiravir and dexamethasone are adopted for use against COVID-19 and currently clinical studies are underway to test their safety and efficacy for treating COVID-19 patients. As per World Health Organization reports, so far more than 16 million people are affected by COVID-19 with a recovery of close to 10 million and deaths at 600,000 globally.
SARS-CoV-2 infection is …
引用总数